SFI
TRML

Susquehanna Fundamental Investments’s Tourmaline Bio TRML Stock Holding History

Susquehanna Fundamental Investments’s Portfolio TRML Stock Details TRML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,402
Closed -$198K – 757
2025
Q2 		$198K Hold
12,402
– – 0.01% 668
2025
Q1 		$189K Sell
12,402
-10,642
-46% -$171K ﹤0.01% 1004
2024
Q4 		$467K Buy
+23,044
New +$580K 0.01% 867

Other funds holding TRML

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.63% 1-Year Est. Return
QUSVM
Qiming U.S. Ventures Management Bellevue, Washington $55.6M AUM 98.09% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.28% 1-Year Est. Return

Susquehanna Fundamental Investments's TRML Position: Q3 2025 in Review

Susquehanna Fundamental Investments sold out of Tourmaline Bio (TRML) in Q3 2025, closing a stake of 12,402 shares — an estimated $198K sold.

Susquehanna Fundamental Investments first reported a position in TRML in Q4 2024 and held it in 3 quarters. The position peaked at $467K in Q4 2024. 134 funds tracked by Wall St. Rank hold TRML as of Q3 2025.

  • Susquehanna Fundamental Investments reported no remaining Tourmaline Bio position as of Q3 2025 after selling out during the quarter.
  • Susquehanna Fundamental Investments sold 12,402 Tourmaline Bio shares in Q3 2025, an estimated $198K.
  • Susquehanna Fundamental Investments first reported a position in Tourmaline Bio in Q4 2024 and held it in 3 quarters.
  • Susquehanna Fundamental Investments's Tourmaline Bio position peaked at $467K in Q4 2024.
  • 134 funds tracked by Wall St. Rank held Tourmaline Bio as of Q3 2025.

Based on Susquehanna Fundamental Investments's 13F filing for Q3 2025, filed 14 Nov 2025.